Search

Bristol-Myers Squibb Co.

Cerrado

SectorSanidad

63.82 -1.25

Resumen

Variación precio

24h

Actual

Mínimo

63.35

Máximo

64.62

Métricas clave

By Trading Economics

Ingresos

638M

3.3B

Ventas

1.5B

13B

P/B

Media del Sector

14.011

57.002

BPA

2.04

Rentabilidad por dividendo

3.87

Margen de beneficios

25.561

Empleados

32,500

EBITDA

1.3B

4.9B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+3.87% upside

Dividendos

By Acuity

Rentabilidad por dividendo

Media del Sector

3.87%

2.22%

Próximas Ganancias

29 oct 2026

Próxima Fecha de Ex Dividendo

2 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

2.2B

130B

Apertura anterior

65.07

Cierre anterior

63.82

Noticias sobre sentimiento de mercado

By Acuity

35%

65%

125 / 340 Clasificación en Healthcare

Bristol-Myers Squibb Co. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ago 2026, 20:06 UTC

Social Media
News
Event

Bristol-Myers Squibb shares are lower after FDA approval of Zenbexus due to concerns over its $29,500 pricing, which may dampen market sentiment.

13 ago 2026, 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

12 ago 2026, 23:56 UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

11 ago 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rising from earlier gains and positioned above their 20-day moving average.

10 ago 2026, 23:51 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. The decline follows three consecutive sessions of gains amid shifting labor market sentiment.

8 ago 2026, 00:01 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, continuing a decline since Friday's close despite being above the 20-day moving average.

7 ago 2026, 23:06 UTC

Bristol-Myers Squibb shares lower in after-market trading, despite maintaining a position above the 20-day moving average. No specific news was identified.

6 ago 2026, 23:26 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, influenced by broader market trends and a stronger U.S. Dollar amid rising jobless claims.

5 ago 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. No specific news was identified to explain the movement.

4 ago 2026, 23:16 UTC

Bristol-Myers Squibb Co. shares gained in after-market trading, reflecting a modest uptick of 0.20% and remaining above their 20-day moving average.

3 ago 2026, 23:02 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

31 jul 2026, 19:16 UTC

News
Social Media

Bristol-Myers Squibb shares rise as multiple analysts raise price targets following strong second-quarter results and an upward revision of annual guidance.

30 jul 2026, 22:51 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, reversing earlier gains and reflecting a notable retreat from earlier highs.

29 jul 2026, 23:36 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, amid rising interest rates and inflation concerns contributing to market volatility. No specific news was identified.

28 jul 2026, 20:06 UTC

News

Bristol-Myers Squibb is rising as it enhances collaboration with Nvidia for AI in drug discovery, improving efficiency in development processes.

27 jul 2026, 22:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news driving the decline amid mixed broader market performance.

24 jul 2026, 17:56 UTC

Bristol-Myers Squibb Co shares are higher, maintaining a positive trajectory since Thursday's close. No specific news was identified to explain today's price action.

23 jul 2026, 00:01 UTC

Bristol-Myers Squibb Co shares are modestly higher in after-market trading, recovering from an earlier dip and remaining above their 20-day moving average.

22 jul 2026, 23:11 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, reaching a notable rise while remaining above the 20-day moving average.

21 jul 2026, 23:36 UTC

Bristol-Myers Squibb Co. shares are near unchanged in after-market trading, remaining above their 20-day moving average amid a solid performance backdrop.

20 jul 2026, 23:41 UTC

Bristol-Myers Squibb Co. shares are trading roughly flat in after-market hours, remaining effectively unchanged since Monday's close amid no specific news.

Comparación entre iguales

Cambio de precio

Bristol-Myers Squibb Co. previsión

Precio Objetivo

By TipRanks

3.87% repunte

Estimación a 12 Meses

Media 66.3 USD  3.87%

Máximo 80 USD

Mínimo 40 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

21 ratings

9

Comprar

11

Mantener

1

Vender

Sentimiento

By Acuity

125 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
help-icon Live chat